Improving survival trends in primary myelofibrosis: An international study

Francisco Cervantes, Brigitte Dupriez, Francesco Passamonti, Alessandro M. Vannucchi, Enrica Morra, John T. Reilly, Jean Loup Demory, Elisa Rumi, Paola Guglielmelli, Elisa Roncoroni, Ayalew Tefferi, Arturo Pereira

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Purpose: Despite the lack of major improvements in the treatment of primary myelofibrosis (PMF), there are recent indications that the survival of patients might have increased over the years. This study was aimed at ascertaining whether survival prolongation has actually occurred in PMF. Patients and Methods: A total of 802 patients diagnosed with PMF in four European countries were compared for the presentation of features and survival according to the diagnostic periods 1980 to 1995 (n = 434) and 1996 to 2007 (n = 368); relative survival was estimated for the two groups. Results: Patients diagnosed between 1996 and 2007 more often had constitutional symptoms (31% v 23%) but a lower incidence of marked anemia (31% v 39%), leukocytosis greater than 25 X 109/L (9% v 13%), and blood blasts (27% v 33%); risk distribution was comparable between the two groups. Median survival was 4.6 years (95% CI, 4.0 to 5.1) for patients from 1980 to 1995 and 6.5 years (95% CI, 5.5 to 7.4) for patients from 1996 to 2007 (P < .001). The latter group of patients showed improved relative survival, especially for women, patients younger than age 65 years, and patients with low or intermediate-1-risk disease. Rates of PMF-attributable mortality at 5 and 10 years were significantly lower in the second period; this reduction in disease-specific mortality occurred across all patient subgroups, except in intermediate-2-risk or high-risk patients. Conclusion: Survival of PMF is steadily improving, except in patients in poor-risk categories. This observation must be taken into account at the time of evaluating the survival impact of newer therapies for PMF, which are currently being tested in these patient subpopulations.

Original languageEnglish (US)
Pages (from-to)2981-2987
Number of pages7
JournalJournal of Clinical Oncology
Volume30
Issue number24
DOIs
StatePublished - Aug 20 2012

Fingerprint

Primary Myelofibrosis
Survival
Mortality
Leukocytosis
Anemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cervantes, F., Dupriez, B., Passamonti, F., Vannucchi, A. M., Morra, E., Reilly, J. T., ... Pereira, A. (2012). Improving survival trends in primary myelofibrosis: An international study. Journal of Clinical Oncology, 30(24), 2981-2987. https://doi.org/10.1200/JCO.2012.42.0240

Improving survival trends in primary myelofibrosis : An international study. / Cervantes, Francisco; Dupriez, Brigitte; Passamonti, Francesco; Vannucchi, Alessandro M.; Morra, Enrica; Reilly, John T.; Demory, Jean Loup; Rumi, Elisa; Guglielmelli, Paola; Roncoroni, Elisa; Tefferi, Ayalew; Pereira, Arturo.

In: Journal of Clinical Oncology, Vol. 30, No. 24, 20.08.2012, p. 2981-2987.

Research output: Contribution to journalArticle

Cervantes, F, Dupriez, B, Passamonti, F, Vannucchi, AM, Morra, E, Reilly, JT, Demory, JL, Rumi, E, Guglielmelli, P, Roncoroni, E, Tefferi, A & Pereira, A 2012, 'Improving survival trends in primary myelofibrosis: An international study', Journal of Clinical Oncology, vol. 30, no. 24, pp. 2981-2987. https://doi.org/10.1200/JCO.2012.42.0240
Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT et al. Improving survival trends in primary myelofibrosis: An international study. Journal of Clinical Oncology. 2012 Aug 20;30(24):2981-2987. https://doi.org/10.1200/JCO.2012.42.0240
Cervantes, Francisco ; Dupriez, Brigitte ; Passamonti, Francesco ; Vannucchi, Alessandro M. ; Morra, Enrica ; Reilly, John T. ; Demory, Jean Loup ; Rumi, Elisa ; Guglielmelli, Paola ; Roncoroni, Elisa ; Tefferi, Ayalew ; Pereira, Arturo. / Improving survival trends in primary myelofibrosis : An international study. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 24. pp. 2981-2987.
@article{01701732f53948a8971ccb4cc50bb39d,
title = "Improving survival trends in primary myelofibrosis: An international study",
abstract = "Purpose: Despite the lack of major improvements in the treatment of primary myelofibrosis (PMF), there are recent indications that the survival of patients might have increased over the years. This study was aimed at ascertaining whether survival prolongation has actually occurred in PMF. Patients and Methods: A total of 802 patients diagnosed with PMF in four European countries were compared for the presentation of features and survival according to the diagnostic periods 1980 to 1995 (n = 434) and 1996 to 2007 (n = 368); relative survival was estimated for the two groups. Results: Patients diagnosed between 1996 and 2007 more often had constitutional symptoms (31{\%} v 23{\%}) but a lower incidence of marked anemia (31{\%} v 39{\%}), leukocytosis greater than 25 X 109/L (9{\%} v 13{\%}), and blood blasts (27{\%} v 33{\%}); risk distribution was comparable between the two groups. Median survival was 4.6 years (95{\%} CI, 4.0 to 5.1) for patients from 1980 to 1995 and 6.5 years (95{\%} CI, 5.5 to 7.4) for patients from 1996 to 2007 (P < .001). The latter group of patients showed improved relative survival, especially for women, patients younger than age 65 years, and patients with low or intermediate-1-risk disease. Rates of PMF-attributable mortality at 5 and 10 years were significantly lower in the second period; this reduction in disease-specific mortality occurred across all patient subgroups, except in intermediate-2-risk or high-risk patients. Conclusion: Survival of PMF is steadily improving, except in patients in poor-risk categories. This observation must be taken into account at the time of evaluating the survival impact of newer therapies for PMF, which are currently being tested in these patient subpopulations.",
author = "Francisco Cervantes and Brigitte Dupriez and Francesco Passamonti and Vannucchi, {Alessandro M.} and Enrica Morra and Reilly, {John T.} and Demory, {Jean Loup} and Elisa Rumi and Paola Guglielmelli and Elisa Roncoroni and Ayalew Tefferi and Arturo Pereira",
year = "2012",
month = "8",
day = "20",
doi = "10.1200/JCO.2012.42.0240",
language = "English (US)",
volume = "30",
pages = "2981--2987",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Improving survival trends in primary myelofibrosis

T2 - An international study

AU - Cervantes, Francisco

AU - Dupriez, Brigitte

AU - Passamonti, Francesco

AU - Vannucchi, Alessandro M.

AU - Morra, Enrica

AU - Reilly, John T.

AU - Demory, Jean Loup

AU - Rumi, Elisa

AU - Guglielmelli, Paola

AU - Roncoroni, Elisa

AU - Tefferi, Ayalew

AU - Pereira, Arturo

PY - 2012/8/20

Y1 - 2012/8/20

N2 - Purpose: Despite the lack of major improvements in the treatment of primary myelofibrosis (PMF), there are recent indications that the survival of patients might have increased over the years. This study was aimed at ascertaining whether survival prolongation has actually occurred in PMF. Patients and Methods: A total of 802 patients diagnosed with PMF in four European countries were compared for the presentation of features and survival according to the diagnostic periods 1980 to 1995 (n = 434) and 1996 to 2007 (n = 368); relative survival was estimated for the two groups. Results: Patients diagnosed between 1996 and 2007 more often had constitutional symptoms (31% v 23%) but a lower incidence of marked anemia (31% v 39%), leukocytosis greater than 25 X 109/L (9% v 13%), and blood blasts (27% v 33%); risk distribution was comparable between the two groups. Median survival was 4.6 years (95% CI, 4.0 to 5.1) for patients from 1980 to 1995 and 6.5 years (95% CI, 5.5 to 7.4) for patients from 1996 to 2007 (P < .001). The latter group of patients showed improved relative survival, especially for women, patients younger than age 65 years, and patients with low or intermediate-1-risk disease. Rates of PMF-attributable mortality at 5 and 10 years were significantly lower in the second period; this reduction in disease-specific mortality occurred across all patient subgroups, except in intermediate-2-risk or high-risk patients. Conclusion: Survival of PMF is steadily improving, except in patients in poor-risk categories. This observation must be taken into account at the time of evaluating the survival impact of newer therapies for PMF, which are currently being tested in these patient subpopulations.

AB - Purpose: Despite the lack of major improvements in the treatment of primary myelofibrosis (PMF), there are recent indications that the survival of patients might have increased over the years. This study was aimed at ascertaining whether survival prolongation has actually occurred in PMF. Patients and Methods: A total of 802 patients diagnosed with PMF in four European countries were compared for the presentation of features and survival according to the diagnostic periods 1980 to 1995 (n = 434) and 1996 to 2007 (n = 368); relative survival was estimated for the two groups. Results: Patients diagnosed between 1996 and 2007 more often had constitutional symptoms (31% v 23%) but a lower incidence of marked anemia (31% v 39%), leukocytosis greater than 25 X 109/L (9% v 13%), and blood blasts (27% v 33%); risk distribution was comparable between the two groups. Median survival was 4.6 years (95% CI, 4.0 to 5.1) for patients from 1980 to 1995 and 6.5 years (95% CI, 5.5 to 7.4) for patients from 1996 to 2007 (P < .001). The latter group of patients showed improved relative survival, especially for women, patients younger than age 65 years, and patients with low or intermediate-1-risk disease. Rates of PMF-attributable mortality at 5 and 10 years were significantly lower in the second period; this reduction in disease-specific mortality occurred across all patient subgroups, except in intermediate-2-risk or high-risk patients. Conclusion: Survival of PMF is steadily improving, except in patients in poor-risk categories. This observation must be taken into account at the time of evaluating the survival impact of newer therapies for PMF, which are currently being tested in these patient subpopulations.

UR - http://www.scopus.com/inward/record.url?scp=84865263436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865263436&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.42.0240

DO - 10.1200/JCO.2012.42.0240

M3 - Article

C2 - 22826273

AN - SCOPUS:84865263436

VL - 30

SP - 2981

EP - 2987

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -